长期的多中心比较显示,单克隆抗体在治疗严重喘时具有相当的疗效
Moritz Z Kayser1, Hendrik Suhling2, Jan Fuge2,3
1Department of Respiratory Medicine and Infectious Disease, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Lower Saxony, Germany. kayser.moritz@mh-hannover.de.
梅波利祖马布 (Mepolizumab),本拉利祖马布 (benralizumab) 和杜比卢马布 (dupilumab) 都有效治疗严重喘,显示出类似的长期益处. 建议对这些生物药物进行治疗反应的早期评估.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重喘治疗已经被单克隆抗体 (生物药物) 彻底改变.
- 梅波利祖马布 (抗IL5),本拉利祖马布 (抗IL5受体α) 和杜皮卢马布 (抗IL4/13) 是主要使用的生物药物.
- 相对的长期疗效数据有限,使治疗选择复杂化.
研究的目的:
- 为了比较现实世界的12个月疗效,mepolizumab,benralizumab和dupilumab在严重的喘中.
- 评估肺功能,恶化率,口服皮质类固醇的使用,喘控制,FeNO水平和反应状态.
主要方法:
- 在12个月内对280名严重喘患者进行了回顾性分析.
- 患者接受的是梅波利祖马布 (46%),本拉利祖马布 (30%) 或杜比卢马布 (24%).
- 在基线,6个月和12个月收集的数据,评估肺功能,恶化,OCS使用,ACT,FeNO和生物喘反应评分 (BARS).
主要成果:
- 所有生物药物显著改善了肺功能,喘控制测试 (ACT) 评分,并减少了口服皮质类固醇 (OCS) 剂量.
- 梅波利祖马布和本拉利祖马布显著降低了恶化率; 梅波利祖马布和杜皮卢马布降低了FeNO水平.
- 在所有组中都观察到高响应率 (BARS),大约一半实现了完全响应,结果在6个月和12个月时相似.
结论:
- 所有评估的生物药物都显示出显著的疗效和严重喘的高反应率.
- 从长远来看,没有任何一种生物药物在临床上比其他药物具有相关优势.
- 治疗反应通常在6个月内实现,并在12个月内维持,支持早期评估疗效.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
09:58A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
